Bacterial resistance: Origins, epidemiology, and impact

Clinical Infectious Diseases

Volumn 36, Issue SUPPL. 1, 2003, Pages

  Livermore, David M ^a  

^a Antibiotic Resistance M/R L   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; DETERGENT; DISINFECTANT AGENT; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LINCOSAMIDE; MACROLIDE; MINOCYCLINE; NOVOBIOCIN; ORGANIC SOLVENT; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; SULBACTAM; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CELL LINEAGE; CORRELATION ANALYSIS; DRUG TRANSPORT; EPIDEMIC; GENE MUTATION; HOSPITAL CARE; HUMAN; HYPERMUTABILITY; INFECTION CONTROL; INTEGRON; KLEBSIELLA PNEUMONIAE; MEDICAL SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MEXR GENE; MEXT GENE; MEXZ GENE; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NFXB GENE; NONHUMAN; PLASMID; PLASMID ADDICTION; PREVALENCE; PRIORITY JOURNAL; REGULATOR GENE; RISK FACTOR; STRAIN IDENTIFICATION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PRESCRIPTIONS, DRUG; TRANSDUCTION, GENETIC;

EID: 0037439518     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344654     Document Type: Article

References (106)

1. Woodford N. Glycopeptide-resistant enterococci: a decade of experience. J Med Microbiol 1998;47:849-62.
2. French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998; 27(Suppl 1):S75-83.
3. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998;41:7-11.
4. Gomez J, Simarro E, Banos V, et al. Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1999;18:358-61.
5. Elting LS, Khardori N, Bodey GP, et al. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990;11:134-8.
6. VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol 1997;18:316-21.
7. Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 1997;24:1131-4.
8. Bridges BA. Hypermutation in bacteria and other cellular systems. Philos Trans R Soc Lond B Biol Sci 2001;356:29-39.
9. Podglajen I, Breuil J, Collatz E. Insertion of a novel DNA sequence, 1S1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. Mol Microbiol 1994;12:105-14.
10. Friedberg EC, Walker GC, Siede W. DNA repair and mutagenesis. Washington, DC: ASM Press, 1995.
11. Rebeck GW, Samson L. Increased spontaneous mutation and alkylation sensitivity of Escherichia coli strains lacking the ogt O6-methylguanine DNA repair methyltransferase. J Bacteriol 1991;173:2068-76.
12. Nema S, Premchandani P, Asolkar MV, et al. Emerging bacterial drug resistance in hospital practice. Indian J Med Sci 1997;51:275-80.
13. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999;43:2736-41.
14. Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001;45:1515-21.
15. Everett MJ, Jin YF, Ricci V, Piddock LJ. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996;40:2380-6.
16. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337-41.
17. Oethinger M, Kern WV, Jellen-Ritter AS, et al. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother 2000;44:10-3.
18. Ysern P, Clerch B, Castano M, et al. Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 1990;5:63-6.
19. Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288:1251-4.
20. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001;3:255-64.
21. Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994;38:1732-41.
22. Lewis K. In search of natural substrates and inhibitors of MDR pumps. J Mol Microbiol Biotechnol 2001;3:247-54.
23. Kohler T, Epp SF, Curty LK, et al. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 1999;181:6300-5.
24. Barbosa TM, Levy SB. Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA. J Bacteriol 2000;182:3467-74.
25. Cohen SP, McMurry LM, Hooper DC, et al. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 1989;33:1318-25.
26. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999;58(Suppl 2):11-8.
27. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
28. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
29. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82.
30. Quinn JP, Studemeister AE, DiVincenzo CA, et al. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis 1988;10:892-8.
31. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:2154-6.
32. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
33. Rice LB. Bacterial monopolists: the bundling and dissemination of antimicrobial resistance genes in gram-positive bacteria. Clin Infect Dis 2000;31:762-9.
34. Hughes VM, Datta N. Conjugative plasmids in bacteria of the "preantibiotic" era. Nature 1983;302:725-6.
35. Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrob Agents 2000;16(Suppl 1):S3-10.
36. Hall RM. Mobile gene cassettes and integrons: moving antibiotic resistance genes in gram-negative bacteria. Ciba Found Symp 1997;207:192-202.
37. Hall RM, Collis CM, Kim MJ, et al. Mobile gene cassettes and integrons in evolution. Ann N Y Acad Sci 1999;870:68-80.
38. Martinez-Freijo P, Fluit AC, Schmitz FJ, et al. Many class I integrons comprise distinct stable structures occurring in different species of Enterobacteriaceae isolated from widespread geographic regions in Europe. Antimicrob Agents Chemother 1999;43:686-9.
39. Chang CY, Chang LL, Chang YH, et al. Characterisation of drug resistance gene cassettes associated with class 1 integrons in clinical isolates of Escherichia coli from Taiwan, ROC. J Med Microbiol 2000;49:1097-102.
40. Enne VI, Livermore DM, Stephens P, et al. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 2001;357:1325-8.
41. Courvalin P. Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 1994;38:1447-51.
42. Bauernfeind A, Chong Y, Lee K. Plasmid-encoded AmpC β-lactamases: how far have we gone 10 years after the discovery? Yonsei Med J 1998;39:520-5.
43. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002;46:1-11.
44. Oliver A, Perez-Diaz JC, Coque TM, et al. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing β-lactamase (CTX-M-10) isolated in Spain. Antimicrob Agents Chemother 2001;45:616-20.
45. Trieu-Cuot P, Arthur M, Courvalin P. Origin, evolution and dissemination of antibiotic resistance genes. Microbiol Sci 1987;4:263-6.
46. Sievert DM, Boulton ML, Stoltman G, et al. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
47. Marshall CG, Broadhead G, Leskiw BK, et al. D-ala-D-ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc Natl Acad Sci USA 1997;94:6480-3.
48. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996;38:409-24.
49. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000;45:183-9.
50. Yuan M, Aucken H, Hall LM, et al. Epidemiological typing of klebsiellae with extended-spectrum β-lactamases from European intensive care units. J Antimicrob Chemother 1998;41:527-39.
51. Essack SY, Hall LM, Pillay DG, et al. Complexity and diversity of Klebsiella pneumoniae stains with extended-spectrum β-lactamases in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob Agents Chemother 2001;45:88-95.
52. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994;264:388-93.
53. Enne VI, Livermore DM, Hall LMC. Sulfonamide resistance in Haemophilus influenzae mediated by sul2 or an insertion in chromosomal folP [abstract 2275]. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
54. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
55. Voss A, Milatovic D, Wallrauch-Schwarz C, et al. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13:50-5.
56. Song JH, Lee NY, Ichiyama S, et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis 1999;28:1206-11.
57. Reacher MH, Shah A, Livermore DM, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000;320:213-6.
58. Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist 1995;1:115-20.
59. Kristinsson KG. Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist 1995;1:121-5.
60. Munoz R, Coffey TJ, Daniels M, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991;164:302-6.
61. M'Zali FH, Heritage J, Gascoyne-Binzi DM, et al. Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated AmpC-type β-lactamase exposed during an outbreak of SHV-5 extended-spectrum β-lactamase in a Leeds hospital. J Antimicrob Chemother 1997;40:823-31.
62. Child JA. A study of β-lactamase mediated antibiotic resistance in clinical isolates originating from Punjab, India [thesis]. London: University of London, 2001.
63. Nordmann P, Ronco E, Naas T, et al. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993;37:962-9.
64. Vahaboglu H, Ozturk R, Aygun G, et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997;41:2265-9.
65. Danel F, Hall LM, Gut D, et al. Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother 1995;35:281-94.
66. Johnson AP, Aucken H, Cavendish S, et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001;48:144.
67. Bure A, Legrand P, Arlet G, et al. Dissemination in five French hospitals of Klebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam. Eur J Clin Microbiol Infect Dis 1988;7:780-2.
68. Arlet G, Rouveau M, Casin I, et al. Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals. J Clin Microbiol 1994;32:2553-8.
69. Bosi C, Davin-Regli A, Bornet C, et al. Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol 1999;37:2165-9.
70. Pitt TL, Kaufmann ME, Patel PS, et al. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996;44:203-10.
71. Casin I, Breuil J, Brisabois A, et al. Multidrug-resistant human and animal Salmonella typhimurium isolates in France belong predominantly to a DT104 clone with the chromosome- and integron-encoded β-lactamase PSE-1. J Infect Dis 1999;179:1173-82.
72. Threlfall EJ. Antimicrobial drug resistance in Salmonella: problems and perspectives in food- and water-borne infections. FEMS Microbiol Rev 2002;26:141-8.
73. Willems RJ, Homan W, Top J, et al. Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals. Lancet 2001;357:853-5.
74. Di Martino P, Livrelli V, Sirot D, et al. A new fimbrial antigen harbored by CAZ-5/SHV-4 - producing Klebsiella pneumoniae strains involved in nosocomial infections. Infect Immun 1996;64:2266-73.
75. MacGowan AP, Bowker KE, Bennett PM, et al. Surveillance of antimicrobial resistance. Lancet 1998;352:1783.
76. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-67.
77. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543-9.
78. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-20.
79. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
80. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2002;35:in press.
81. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000;3:489-95.
82. Nash JM. The antibiotics crisis: we're in the midst of an escalating arms race with the microbe, and we may be losing. Time 2001;157:90-2.
83. Interagency Task Force on Antibiotic Resistance. A Public health action plan to combat antimicrobial resistance. Atlanta, GA: Centers for Diseases Control and Prevention, 2001.
84. Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-99.
85. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos Trans R Soc Lond B Biol Sci 1999;354:721-38.
86. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441-6.
87. Kataja J, Huovinen P, Muotiala A, et al. Clonal spread of group A streptococcus with the new type of erythromycin resistance. Finnish Study Group for Antimicrobial Resistance. J Infect Dis 1998;177:786-9.
88. Chiew YF, Yeo SF, Hall LM, et al. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. J Antimicrob Chemother 1998;41:247-51.
89. Bouma JE, Lenski RE. Evolution of a bacteria/plasmid association. Nature 1988;335:351-2.
90. Lenski RE. The cost of antibiotic resistance - from the perspective of a bacterium. Ciba Found Symp 1997;207:131-40.
91. Rawlings DE. Proteic toxin-antitoxin, bacterial plasmid addiction systems and their evolution with special reference to the pas system of pTF-FC2. FEMS Microbiol Lett 1999;176:269-77.
92. King JW, White MC, Todd JR, et al. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992;14:908-15.
93. Betts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984;100:219-22.
94. Bradley SJ, Wilson AL, Allen MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261-6.
95. Levison M, Evangelista A, Hayburn J, et al. The effects of formulary conversion from ceftazidime to cefepime on in vitro susceptibility of Enterobacter cloacae at 7 medical centers [abstract 92]. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
96. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-7.
97. Rice LB. Successful interventions for gram-negative resistance to extended-spectrum •-lactam antibiotics. Pharmacotherapy 1999;19:120S-8S.
98. Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
99. Friedland IR, Funk E, Khoosal M, et al. Increased resistance to amikacin in a neonatal unit following intensive amikacin usage. Antimicrob Agents Chemother 1992;36:1596-600.
100. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51.
101. John JF. Antibiotic cycling: is it ready for prime time? Infect Control Hosp Epidemiol 2000;21:9-11.
102. Pihlajamaki M, Kotilainen P, Kaurila T, et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001;33:483-8.
103. Millar MR, Russell E, Karcher AM, et al. Prescribing quality is not synonymous with cost minimization for antibiotics. J Antimicrob Chemother 2001;47:367-8.
104. Kern WV, Oethinger M, Jellen-Ritter, et al. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2000;44:814-20.
105. Marton A, Meszner Z. Epidemiological studies on drug resistance in Streptococcus pneumoniae in Hungary: an update for the 1990s. Microb Drug Resist 1999;5:201-5.
106. Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000;46:347-50.